Intermediate-dose cyclophosphamide and bortezomib for PBSC mobilization in multiple myeloma

Although the incorporation of bortezomib into induction regimens has improved, response rates in patients with multiple myeloma (MM), the role of bortezomib in the, peripheral blood stem cell (PBSC) mobilization remains unclear. We assessed the, PBSC mobilization efficacy, safety, and disease response of intermediate-dose, cyclophosphamide and bortezomib in the PBSC mobilization. Twenty-one patients with, newly diagnosed MM were enrolled in a phase II, non-randomized study that used, bortezomib (1.3  mg/m2/day on days 1, 4, 8, and 11) and intermediate-dose, cyclophosphamide (2 g/m2/day on days 2, 3) (Bor-ID-CY).

Source: Transfusion and Apheresis Science - January 31, 2023 Category: Hematology Authors: Aiko Sawazaki, Chiharu Sugimori, Masaki Yamaguchi, Shinji Nakao Source Type: research